" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus
ConditionSystemic Lupus Erythematosus
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorSouth Valley University
About this trial
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.
Eligibility criteria
Qualifiers
Adult aged 18-60 years
Diagnosed as SLE per 2019 EULAR/ACR classification criteria.
Presence of at least one cutaneous manifestation (acute, subacute, or chronic).
Willing to provide written informed consent for participation and genetic testing
Disqualifiers
Overlap autoimmune syndromes (e.g., dermatomyositis, systemic sclerosis).
Systemic infection, malignancy, or pregnancy.
Use of biologic therapy or immunosuppressive pulses within one month.
Trial design
Treatments tested in this trial
- TREX1 gene polymorphisms
Treatment groups
90 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov